Numinus Wellness (OTCMKTS:LKYSF – Get Free Report) and biote (NASDAQ:BTMD – Get Free Report) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, earnings, analyst recommendations, dividends, institutional ownership, valuation and risk.

21.7% of biote shares are owned by institutional investors. 32.4% of biote shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

This table compares Numinus Wellness and biote”s revenue, earnings per share (EPS) and valuation.

biote has higher revenue and earnings than Numinus Wellness. Numinus Wellness is trading at a lower price-to-earnings ratio than biote, indicating that it is currently the more affordable of the two stocks.

This is a breakdown of current ratings for Numinus Wellness and biote, as provided by MarketBeat.

biote has a consensus target price of $2.62, indicating a potential upside of 77.36%. Given biote’s stronger consensus rating and higher probable upside, analysts plainly believe biote is more favorable than Numinus Wellness.

This table compares Numinus Wellness and biote’s net margins, return on equity and return on assets.

biote beats Numinus Wellness on 11 of the 12 factors compared between the two stocks.

(Get Free Report)

Numinus Wellness, Inc. operates as a Canadian health care company empowering healing and wellness through the development and delivery of safe, evidence-based psychedelic-assisted therapies for mental illness, substance abuse and trauma. The Numinus model comprises psychedelic production, clinical research and clinical care, with a Health Canada-licenced research facility, seasoned medical team and growing network of clinics. The company’s licence allows for a range of research activities and import, export and distribution of psychedelic substances including DMT, ketamine, LSD, MDMA, mescaline, psilocybin, psilocin. It operates through the following segments: Salvation Botanicals, Numinus Health and Salvation Bioscience. The Salvation Botanicals segment engages in psychedelic substance research, developing intellectual property while offering analytics services for revenue generation. Its laboratory provides services including cultivation, analytical testing, product research and development, and ancillary services in the area of psychedelics. The Numinus Health segment operates the wellness centre where professional therapists and health professionals use supportive therapies and

(Get Free Report)

biote Corp. operates in practice-building business within the hormone optimization space. It trains physicians and nurse practitioners in hormone optimization using bioidentical hormone replacement pellet therapy in men and women experiencing hormonal imbalance. The company offers Biote Method, a comprehensive end-to-end practice building platform that provides Biote-certified practitioners with the components developed for practitioners in the hormone optimization space comprising Biote Method education, training, and certification services; practice management software that allows Biote-certified practitioners to order, track, and manage hormone optimization product inventory and other administrative requirements; inventory management software to monitor pellet inventory; and information regarding available hormone replacement therapy products, as well as digital and point-of-care marketing support. It also sells dietary supplements under the Biote brand; and sterile pellet insertion kits that is used with hormone optimization therapies for male and female. The company was founded in 2012 and is headquartered in Irving, Texas.

Receive News & Ratings for Numinus Wellness Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Numinus Wellness and related companies with MarketBeat.com's FREE daily email newsletter.

CenterPoint Energy (NYSE:CNP) & NorthWestern (NASDAQ:NWE) Critical Contrast